Shefali Agarwal
Chief Executive Officer at VALERIO THERAPEUTICS
Net worth: 76 997 $ as of 2024-03-30
Profile
Shefali Agarwal is currently the Chairman, President & Chief Executive Officer at Valerio Therapeutics SA, an Independent Director at Fate Therapeutics, Inc., and an Independent Director at Gritstone bio, Inc. She previously served as the Chief Medical Officer at SQZ Biotechnologies Co. from 2017 to 2018 and as the Executive VP, Chief Medical & Development Officer at Epizyme, Inc. from 2018 to 2022.
Dr. Agarwal holds a graduate degree from The Johns Hopkins University, a doctorate degree from Karnataka University, and a graduate degree from Merrick School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
FATE THERAPEUTICS, INC.
0.01% | 2023-06-05 | 10,490 ( 0.01% ) | 76 997 $ | 2024-03-30 |
GRITSTONE BIO, INC.
-.--% | 2023-06-15 | 0 ( -.--% ) | - $ | 2024-03-30 |
Shefali Agarwal active positions
| Companies | Position | Start |
|---|---|---|
| FATE THERAPEUTICS, INC. | Director/Board Member | 2019-07-14 |
| GRITSTONE BIO, INC. | Director/Board Member | 2021-05-31 |
| VALERIO THERAPEUTICS | Chief Executive Officer | 2022-04-05 |
Former positions of Shefali Agarwal
| Companies | Position | End |
|---|---|---|
| EPIZYME, INC. | Chief Tech/Sci/R&D Officer | 2022-04-05 |
| SQZ BIOTECHNOLOGIES COMPANY | Chief Tech/Sci/R&D Officer | 2018-04-30 |
Training of Shefali Agarwal
| The Johns Hopkins University | Graduate Degree |
| Karnataka University | Doctorate Degree |
| Merrick School of Business | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Shefali Agarwal
